



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/623,114	07/18/2003	Yerramilli V.S.N. Murthy	051091-2001	4452
23838	7590	05/02/2008	EXAMINER	
KENYON & KENYON LLP 1500 K STREET N.W. SUITE 700 WASHINGTON, DC 20005				KIM, JENNIFER M
ART UNIT		PAPER NUMBER		
1617				
			MAIL DATE	DELIVERY MODE
			05/02/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/623,114	MURTHY ET AL.	
	Examiner	Art Unit	
	Jennifer Kim	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on January 31, 2008.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 25-49 is/are pending in the application.

4a) Of the above claim(s) 38-48 is/are withdrawn from consideration.

5) Claim(s) 34-37 is/are allowed.

6) Claim(s) 25-33, 49 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

The amendment filed January 31, 2008 have been received and entered into the application.

Action Summary

The rejection of claims 25-35 and 37 under 35 U.S.C. 103(a) as being unpatentable over Nagabhushan (U.S.Patent No. 4,311,857) in view of Bundgaard (1985) is being maintained for the reasons stated in the previous Office Action. However, the rejection is modified in this Office Action to include newly added claim 49 and to exclude allowable claims 34, 35 and 37.

The rejection of claim 36 under 35 U.S.C. 103(a) as being unpatentable over Nagabhushan (U.S.Patent No. 4,311,857) in view of Bundgaard (1985) as applied to claims 25-35 above, and further in view of Shuster et al. (US 2004/0198704 A1) is hereby expressly withdrawn in view of Applicants' declaration.

Allowable Subject Matter

In view of Applicants' declaration, claims 34-37 are allowed.

Response to Arguments

Applicants' arguments filed January 31, 2008 have been fully considered but they are not persuasive. Applicants essentially argue that the composition claimed in claim 25, which includes the combination of a first ester prodrug of florfenicol and a second ester prodrug of florfenicol formulated as a composition for administration to a mammal by injection, however, has unexpected advantages that are not disclosed or suggested in either Nagabhushan or Bundgaard. This is not found persuasive because the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art.

See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, it would have been obvious to one of ordinary skill in the art to employ ester derivatives of florfenicol including florfenicol propionate and florfenicol acetate etc.. taught by Nagabhushan in a single formulation for parenteral administration because ester prodrugs taught by Nagabhushan have beneficial effect in parenteral formulation because of they increase the aqueous solubility of drugs containing a hydroxyl group such as florfenicol and this is well known and recognized effective means of preparing parenteral formulation as taught by Bundgaard. The cited references teach the common utility of florfenicol in ester formulation. The motivation for combining the components flows from their individually known common utility (see *In re Kerkhoven*, 205 USPQ 1069(CCPA

1980)). Therefore, the claimed invention, as a whole, would have been obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 25-33 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nagabhushan (U.S.Patent No. 4,311,857) of record in view of Bundgaard (1985).

Nagabhushan teaches a pharmaceutical composition comprising D-(threo)-1-p-methylsulfonylphenyl-2-chloroacetamido-3-fluoro-1-propanol (also known as **florfenicol**) together with a compatible pharmaceutically acceptable carrier. (column 10, lines 5-10, column 20 lines 10-11). Nagabhushan demonstrates that above composition can be formulated in an injectable solution with concentration of 250mg/ml of florfenicol as an active drug. (column 11, lines 20-31, column 12, lines 55-61, Formulation 5). Nagabhushan teaches that the ester derivatives of florfenicol including formic, acetic, propionic, triethylacetic, **butyric**, isobutyric and valeric etc., are also antibacterially active as florfenicol. (column 4 lines 22-60). Nagabhushan teaches that the composition can be formulated to be administered parenterally via intramuscular injection and that the dosage to be administered depends on the stage and severity of

the injection, the susceptibility of the infecting organism to the antibacterial and the individual characteristics of the animal species being treated. (column 10, lines 55-66). Nagabhushan teaches that **propylene glycol** is compatible with florfenicol. (column 11, lines 5-20, formulations).

Nagabhushan does not expressly teach combinations of florfenicol esters in a single formulation and the specific concentration of florfenicol.

Bundgaard teaches that ester formation has long been recognized as an effective means of increasing the aqueous solubility of drugs containing a hydroxyl group, with the aim of developing prodrug preparation suitable for parenteral administration. (page 7, last sentence). Bundgaard teaches that esters convert rapidly in vivo to the active parent drug by hydrolysis. (page 8, second paragraph).

It would have been obvious to one of ordinary skill in the art to employ ester derivatives of florfenicol including florfenicol butyrate, florfenicol propionate and florfenicol acetate etc.. taught by Nagabhushan in a single formulation for parenteral administration because ester prodrugs taught by Nagabhushan have beneficial effect in parenteral formulation because they increase the aqueous solubility of drugs containing a hydroxyl group such as florfenicol and this is well known and recognized effective means of preparing parenteral formulation as taught by Bundgaard. One would have been motivated to make such a modification in order to achieve the active florfenicol in vivo rapidly by hydrolysis of prodrug of florfenicol ester taught by Nagabhushan. Further, to employ more than one active esters of florfenicol in a single formulation is obvious because each of the esters of florfenicol have antibacterial

activity as taught by Nagabhushan. The motivation for combining the components flows from their individually known common utility (see *In re Kerkhoven*, 205 USPQ 1069(CCPA 1980)). With regard to the property of the composition forms a drug depot when injected into a mammal is obvious because the obvious composition taught by Nagabhushan as modified by Bundgaard constitutes with the same active agents cannot have mutually exclusive properties. Further, the specific concentration of florfenicol set forth in the claim is obvious because Nagabhushan demonstrates injectable composition of active agent in concentration of 250mg/ml and that the dosage to be administered depends on the stage and severity of the injection, the susceptibility of the infecting organism to the antibacterial and the individual characteristics of the animal species being treated. Therefore, one of ordinary skill in the art would have been motivate to optimize the concentrations of the parenteral formulation of Nagabhushan as modified by Bundgaard for the specific individuals being treated as determined by their diagnosis and the progress in their condition.

THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1617

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic

Art Unit: 1617

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jennifer Kim/
Primary Examiner, Art Unit 1617

Jmk
April 25, 2008